Pelthos Therapeutics Inc. PTHS revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Pelthos Therapeutics Inc. reported revenue across 2 business segments; the largest, Commercial Operations Segment, was $16.2M, 96.5% of the filed sum.
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Commercial Operations Segment$16.2M96.5%no prior
- Research And Development Operations Segment$589K3.5%no prior
Members sum to the consolidated $16.8M for this period.
- Net Product$16.2M96.5%no prior
- License And Collaboration$589K3.5%no prior
Members sum to the consolidated $16.8M for this period.
- Commercial Operations Segment$10.7M97.8%no prior
- Research And Development Operations Segment$241K2.2%no prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.